Haemonetics Q4 Earnings Call Highlights
Key takeaways
- Haemonetics Q4 Earnings Call Highlights Market Beat Mon, May 11, 2026 at 2:04 AM GMT+7 8 min read HAE Haemonetics logo Key Points Interested in Haemonetics Corporation?
- Haemonetics reported fiscal Q4 revenue of $346 million, up 5% reported and 9% organically excluding CSL, with adjusted EPS of $1.29.
- Plasma and Blood Management Technologies were the main growth drivers, while Interventional Technologies remained weak.
Haemonetics Q4 Earnings Call Highlights Market Beat Mon, May 11, 2026 at 2:04 AM GMT+7 8 min read HAE Haemonetics logo Key Points Interested in Haemonetics Corporation? Here are five stocks we like better.
Haemonetics reported fiscal Q4 revenue of $346 million, up 5% reported and 9% organically excluding CSL, with adjusted EPS of $1.29. For the full year, revenue reached $1.3 billion and adjusted EPS was $4.96, helped by stronger margins and free cash flow.
Plasma and Blood Management Technologies were the main growth drivers, while Interventional Technologies remained weak. Plasma grew 13% organically in the quarter, and Blood Management Technologies posted a record quarter, but Interventional Technologies revenue fell 10% due to softness in vascular closure and related procedures.